Fig. 2
From: Class effects of SGLT2 inhibitors on cardiorenal outcomes
Heart failure hospitalization (HHF), HHF and cardiovascular (CV) death, and major adverse cardiovascular event (MACE) event rates per 1000 patients in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA–REG OUTCOME), and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trials. Statistical outcomes displayed as hazard ratio, 95% confidence interval, p-value. HR hazard ratio, DAPA dapagliflozin, CANA canagliflozin, EMPA empagliflozin, PLB placebo